Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.158.00 CHF
Change Today +0.30 / 0.19%
Volume 9.0K
As of 6:58 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cosmo pharmaceuticals spa (COPN) Snapshot

Open
SFr.159.40
Previous Close
SFr.157.70
Day High
SFr.160.00
Day Low
SFr.157.20
52 Week High
07/9/14 - SFr.193.70
52 Week Low
05/7/14 - SFr.114.00
Market Cap
2.3B
Average Volume 10 Days
12.8K
EPS TTM
SFr.5.08
Shares Outstanding
14.4M
EX-Date
04/28/15
P/E TM
29.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for COSMO PHARMACEUTICALS SPA (COPN)

Related News

No related news articles were found.

cosmo pharmaceuticals spa (COPN) Related Businessweek News

No Related Businessweek News Found

cosmo pharmaceuticals spa (COPN) Details

Cosmo Pharmaceuticals S.p.A. operates as a specialty pharmaceutical company primarily in Italy. The company develops, licenses, and commercializes proprietary pharmaceutical products, primarily for the treatment of inflammatory bowel diseases, colon infections, and other colon diseases, as well as topically treated skin disorders; and manufactures pharmaceutical products for third parties and provides related services. Its products comprise Lialda, Mezavant, and Mesavancol proprietary formulations for mild to moderate ulcerative colitis; Uceris and Cortiment products for mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product for intestinal disorders. The company also develops various products, including CB-17-01 Methylene Blue MMX, a vital dye which stains the living cells that is in Phase III clinical trials for colon cancer; SIC 8000, a submucosal injectable composition developed to reduce the risk of perforation when resecting flat polyps and to allow the resection of large polyps in one piece; Rifamycin SV MMX, a semisynthetic, orally poorly absorbable antibiotic for the treatment of bacterial infections of the colon, which has completed phase III clinical trials in traveler’s diarrhea; CB-03-01, a steroidal anti-androgen drug, cortexolone 17a-proprionate (CB-03-01) 1% cream, targeted at acne, alopecia, hirsutism and possibly seborrhea that has Phase II clinical trials for acne; CB-06-02, a tellurium-based compound for the topical treatment of HPV and genital warts that is in Phase II trial; and CB-06-01, a topical antibiotic for the treatment of acne, which in Phase II trial. The company is headquartered in Luxembourg.

178 Employees
Last Reported Date: 03/25/15

cosmo pharmaceuticals spa (COPN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €1.9M
Founder and Chairman
Total Annual Compensation: €1.6M
Chief Financial Officer, Head of Investor Rel...
Total Annual Compensation: €981.4K
Compensation as of Fiscal Year 2014.

cosmo pharmaceuticals spa (COPN) Key Developments

Cosmo Pharmaceuticals S.p.A. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Cosmo Pharmaceuticals S.p.A. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenues of EUR 79.6 million compared to EUR 56.4 million a year ago. Profit before taxes was EUR 108.9 million compared to EUR 71.7 million a year ago. Net profit was EUR 73.3 million or EUR 5.11 per share compared to EUR 68.7 million or EUR 4.81 per share a year ago.

Cosmo Pharmaceuticals S.p.A., 2014 Earnings Call, Mar 25, 2015

Cosmo Pharmaceuticals S.p.A., 2014 Earnings Call, Mar 25, 2015

Cosmo Pharmaceuticals S.p.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM

Cosmo Pharmaceuticals S.p.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Alessandro E. Della Chà, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COPN:SW SFr.158.00 CHF +0.30

COPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.10 USD +3.73
Depomed Inc $23.86 USD +0.60
Durect Corp $2.20 USD +0.23
Supernus Pharmaceuticals Inc $12.82 USD +0.02
Veloxis Pharmaceuticals A/S kr0.84 DKK +0.085
View Industry Companies
 

Industry Analysis

COPN

Industry Average

Valuation COPN Industry Range
Price/Earnings 27.8x
Price/Sales 25.0x
Price/Book 12.9x
Price/Cash Flow 27.5x
TEV/Sales 24.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COSMO PHARMACEUTICALS SPA, please visit www.cosmopharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.